Literature DB >> 14993644

Vaccine potential of a murine gammaherpesvirus-68 mutant deficient for ORF73.

Polly Fowler1, Stacey Efstathiou1.   

Abstract

A murine gammaherpesvirus (MHV-68) containing a deletion of the putative plasmid maintenance protein ORF73 exhibits a severe latency deficit. In this study the ability of an ORF73 deletion mutant (Delta73) to confer in vivo protection against subsequent challenge with wild-type virus has been examined. Vaccination studies have shown that Delta73 vaccination reduced latent infection of wild-type challenge virus to a level below the limit of detection. These results indicate that a live-attenuated gammaherpesvirus that cannot persist is an effective vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14993644     DOI: 10.1099/vir.0.19760-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics.

Authors:  Joshua J Obar; Douglas C Donovan; Sarah G Crist; Ondine Silvia; James P Stewart; Edward J Usherwood
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

2.  Murine gammaherpesvirus 68 LANA is essential for virus reactivation from splenocytes but not long-term carriage of viral genome.

Authors:  Clinton R Paden; J Craig Forrest; Nathaniel J Moorman; Samuel H Speck
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

3.  Importance of antibody in virus infection and vaccine-mediated protection by a latency-deficient recombinant murine γ-herpesvirus-68.

Authors:  Michael L Freeman; Claire E Burkum; David L Woodland; Ren Sun; Ting-Ting Wu; Marcia A Blackman
Journal:  J Immunol       Date:  2011-12-23       Impact factor: 5.422

Review 4.  Prospects of a novel vaccination strategy for human gamma-herpesviruses.

Authors:  Ting-Ting Wu; Marcia A Blackman; Ren Sun
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

5.  Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.

Authors:  Qingmei Jia; Michael L Freeman; Eric J Yager; Ian McHardy; Leming Tong; DeeAnn Martinez-Guzman; Tammy Rickabaugh; Seungmin Hwang; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

6.  A persistent virus vector confers superior anti-tumor immunity, compared with a non-persistent vector.

Authors:  W Zhang; T Zhang; M-J Turk; E J Usherwood
Journal:  Cancer Immunol Immunother       Date:  2010-05       Impact factor: 6.968

7.  An essential role for γ-herpesvirus latency-associated nuclear antigen homolog in an acute lymphoproliferative disease of cattle.

Authors:  Leonor Palmeira; Océane Sorel; Willem Van Campe; Christel Boudry; Stefan Roels; Françoise Myster; Anca Reschner; Pierre G Coulie; Pierre Kerkhofs; Alain Vanderplasschen; Benjamin G Dewals
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

8.  Vaccination against a hit-and-run viral cancer.

Authors:  Philip G Stevenson; Janet S May; Viv Connor; Stacey Efstathiou
Journal:  J Gen Virol       Date:  2010-06-23       Impact factor: 3.891

9.  Olfactory Entry Promotes Herpesvirus Recombination.

Authors:  Wanxiaojie Xie; Kimberley Bruce; Helen E Farrell; Philip G Stevenson
Journal:  J Virol       Date:  2021-09-15       Impact factor: 5.103

10.  Gammaherpesvirus Colonization of the Spleen Requires Lytic Replication in B Cells.

Authors:  Clara Lawler; Marta Pires de Miranda; Janet May; Orry Wyer; J Pedro Simas; Philip G Stevenson
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.